Liver abnormalities and endocrine diseases

Best Practice and Research: Clinical Gastroenterology

Volumn 27, Issue 4, 2013, Pages 553-563

  Burra, Patrizia ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Addison's disease; Adrenocortical dysfunction; Alcoholic liver disease; Amenorrhoea; Amiodarone; Androgens; Autoimmune diseases; Cirrhosis; Coagulation; Cushing's syndrome; Diabetes; Gonadal dysfunction; Gonadotropin; Growth hormone; Hepatitis; Hyperlipidaemia; Hyperthyroidism; Hypogonadism; Hypothyroidism; Infertility; Insulin resistance; Liver transplantation; Metabolic syndrome; Non alcoholic steatohepatitis; Obesity; Oestrogens; Progesterone; Propylthiouracil; Sexual dysfunction; Steatosis; Thyrotoxicosis

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMIODARONE; ANDROGEN; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBAMAZEPINE; ESTROGEN; GLUCOCORTICOID; GROWTH HORMONE; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; LIOTHYRONINE; LOW MOLECULAR WEIGHT HEPARIN; MEFLOQUINE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROPYLTHIOURACIL; SOMATOMEDIN C; SORAFENIB; THYROGLOBULIN; THYROXINE; UNINDEXED DRUG;

ADDISON DISEASE; ADRENAL CORTEX INSUFFICIENCY; ADRENAL INSUFFICIENCY; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; AMENORRHEA; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE THYROIDITIS; BLEEDING; BLOOD CLOTTING DISORDER; BUDD CHIARI SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTASIS; CLINICAL PRACTICE; CUSHING SYNDROME; DECOMPENSATED LIVER CIRRHOSIS; DRUG MONITORING; ENDOCRINE DISEASE; FATTY LIVER; FEMALE INFERTILITY; FEMINIZATION; FIBRINOLYSIS; HEART INFARCTION; HEMOCHROMATOSIS; HEPATITIS C; HORMONE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; HYPOTHYROIDISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOLYSIS; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; LOW DRUG DOSE; METABOLIC DISORDER; METABOLIC REGULATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; PELIOSIS HEPATIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY HYPERPARATHYROIDISM; PRIMARY PREVENTION; SECONDARY PREVENTION; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SUBACUTE THYROIDITIS; THYROID DISEASE; THYROTOXICOSIS; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

EID: 84885174050     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2013.06.014     Document Type: Review

References (64)

1. Malik R, Hodgson H. The relationship between the thyroid gland and the liver. QJM 2002;95:559-69
2. Laycock MA, Pascuzzi RM. The neuromuscular effects of hypothyroidism. Semin Neurol 1991;11:288-94
3. Kinney EL, Wright RJ, Caldwell JW. Value of clinical features for distinguishing myxedema ascites from other forms of ascites. Comput Biol Med 1989;19:55-9 (Pubitemid 19002752)
4. Baker A, Kaplan M, Wolfe H. Central congestive fibrosis of the liver in myxedema ascites. Ann Intern Med 1972;77:927-9
5. Klein I, Levey GS. Unusual manifestations of hypothyroidism. Arch Intern Med 1984;144:123-8 (Pubitemid 14217974)
6. Van SteenbergenW, Fevery J, De Vos R, Leyten R, Heirwegh KP, De Groote J. Thyroid hormones and the hepatic handling of bilirubin. I. Effects of hypothyroidism and hyperthyroidism on the hepatic transport of bilirubin mono-and diconjugates in the Wistar rat. Hepatology 1989;9:314-21 (Pubitemid 19063320)
7. Gaitan E, Cooper DS. Primary hypothyroidism. Curr Ther Endocrinol Metab 1997;6:94-8
8. Thompson Jr P, Strum D, Boehm T, Wartofsky L. Abnormalities of liver function tests in tyrotoxicosis. Mil Med 1978;143: 548-51. (Pubitemid 8405935)
9. Doran GR. Serum enzyme disturbances in thyrotoxicosis and myxoedema. J R Soc Med 1978;71:189-94
10. Sola J, Pardo-Mind?n FJ, Zozaya J, Quiroga J, Sangro B, Prieto J. Liver changes in patients with hyperthyroidism. Liver 1991; 11:193-7
11. Elias R, Dean DS, Barsness GW. Hepatic dysfunction in hospitalized patients with acute thyrotoxicosis: a decade of experience. Endocrinology 2012:1-6
12. Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab 1997;82:1727-33 (Pubitemid 127495175)
13. Levy M. Propylthiouracil hepatotoxicity. A review and case presentation. Clin Pediatr (Phila) 1993;32:25-9 (Pubitemid 23037194)
14. Golding PL, Smith M, Williams R. Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med 1973;55:772-82
15. Elta GH, Sepersky RA, Goldberg MJ, Connors CM, Miller KB, Kaplan MM. Increased incidence of hypothyroidism in primary biliary cirrhosis. Dig Dis Sci 1983;28:971-5 (Pubitemid 14232080)
16. Silveira MG, Mendes FD, Diehl NN, Enders FT, Lindor KD. Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int 2009;29:1094-100
17. Pateron D, Hartmann DJ, Duclos-Vallee JC, Jouanolle H, Beaugrand M. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J Hepatol 1993;17:417-9 (Pubitemid 23134944)
18. Huang MJ, Liaw YF. Clinical associations between thyroid and liver diseases. J Gastroenterol Hepatol 1995;10:344-50
19. Burra P, Franklyn JA, Ramsden DB, Elias E, Sheppard MC. Severity of alcoholic liver disease and markers of thyroid and steroid status. Postgrad Med J 1992;68:804-10
20. Burra P, Fitch NJ, Kapadi A, Franklyn JA, Sheppard MC, Ramsden DB, et al. The effects of ethanol, 3,5,30-triiodothyronine (T3) and oestradiol (E2) on thyroid hormone nuclear receptor expression in human hepatocyte primary cultures. Alcohol Alcohol 1995;30:219-21
21. Huang MJ, Liaw YF. Thyroxine-binding globulin in patients with chronic hepatitis B virus infection: different implications in hepatitis and hepatocellular carcinoma. Am J Gastroenterol 1990;85:281-4
22. L?Age M, Meinhold H, Wenzel KW, Schleusener H. Relations between serum levels of TSH, TBG, T4, T3, rT3 and various histologically classified chronic liver diseases. J Endocrinol Invest 1980;3:379-83 (Pubitemid 11140915)
23. Oren R, Sikuler E, Wong F, Blendis LM, Halpern Z. The effects of hypothyroidism on liver status of cirrhotic patients. J Clin Gastroenterol 2000;31:162-3
24. Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997;7:891-6 (Pubitemid 28041664)
25. Flohr F, Harder J, Seufert J, Blum HE, Spangenberg HC. Hypothyroidism in patients with hepatocellular carcinoma treated by transarterial chemoembolization. Hepatology 2008;47:2144 (Pubitemid 351945586)
26. Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 2008;19:265-8 (Pubitemid 351201706)
27. Maheshwari A, Thuluvath PJ. Endocrine diseases and the liver. Clin Liver Dis 2011;15:55-67
28. Boulton R, Hamilton MI, Dhillon AP, Kinloch JD, Burroughs AK. Subclinical Addison?s disease: a cause of persistent abnormalities in transaminase values. Gastroenterology 1995;109:1324-7
29. Fede G, Spadaro L, Tomaselli T, Privitera G, Germani G, Tsochatzis E, et al. Adrenocortical dysfunction in liver disease: a systematic review. Hepatology 2012;55:1282-91
30. Marik PE. Adrenal-exhaustion syndrome in patients with liver disease. Intensive Care Med 2006;32:275-80 (Pubitemid 43251149)
31. O?Beirne J, Holmes M, Agarwal B, Bouloux P, Shaw S, Patch D, et al. Adrenal insufficiency in liver disease - what is the evidence? J Hepatol 2007;47:418-23 (Pubitemid 47176168)
32. Stewart PM, Burra P, Shackleton CH, Sheppard MC, Elias E. 11 Beta-hydroxysteroid dehydrogenase deficiency and glucocorticoid status in patients with alcoholic and non-alcoholic chronic liver disease. J Clin Endocrinol Metab 1993;76:748-51 (Pubitemid 23086499)
33. Lindgren A, Olsson R. Liver damage from low-dose oral contraceptives. J Intern Med 1993;234:287-92 (Pubitemid 23263416)
34. Kreek MJ. Female sex steroids and cholestasis. Semin Liver Dis 1987;7:8-23 (Pubitemid 17059222)
35. Reyes H, Gonzalez MC, Ribalta J, Aburto H, Matus C, Schramm G, et al. Prevalence of intrahepatic cholestasis of pregnancy in Chile. Ann Intern Med 1978;88:487-93 (Pubitemid 8330294)
36. Weinberger M, Garty M, Cohen M, Russo Y, Rosenfeld JB. Ultrasonography in the diagnosis and follow-up of hepatic sinusoidal dilatation. Arch Intern Med 1985;145:927-9 (Pubitemid 15033265)
37. Karagiannis A, Harsoulis F. Gonadal dysfunction in systemic diseases. Eur J Endocrinol 2005;152:501-13 (Pubitemid 40575794)
38. De Maria N, Colantoni A, Van Thied D. The liver and endoscrine function. In: Becker KL, Bilezikian John P, Bremner William J, editors. Principles and practice of endocrinology and metabolism. Wilkins; 2000. p. 1870-85
39. Cox TM, Kelly AL. Haemochromatosis: an inherited metal and toxicity syndrome. Curr Opin Genet Dev 1998;8:274-81 (Pubitemid 28340076)
40. Burra P. Sexual dysfunction after liver transplantation. Liver Transpl 2009;(15 Suppl. 2):S50-6
41. Burra P, Germani G, Masier A, De Martin E, Gambato M, Salonia A. Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure? Transplantation 2010;89:1425-9
42. Lomonaco R, Chen J, Cusi K. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Ther Adv Endocrinol Metab 2011;2:211-25
43. Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006;91:1081-6 (Pubitemid 43357784)
44. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51:445-53
45. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12 (Pubitemid 32151228)
46. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005;22:1141-5 (Pubitemid 41224170)
47. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23 (Pubitemid 36397405)
48. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004;39:909-14 (Pubitemid 38428928)
49. Donaghy A, Ross R, Gimson A, Hughes SC, Holly J, Williams R. Growth hormone, insulinlike growth factor-1, and insulin like growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology 1995;21:680-8
50. Takahashi Y. Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver. Endocr J 2012;59: 955-62
51. Ichikawa T, Nakao K, Hamasaki K, Furukawa R, Tsuruta S, Ueda Y, et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int 2007;1: 287-94
52. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 2003;14:365-70 (Pubitemid 37236957)
53. Franchini M, Lippi G, Manzato F, Vescovi PP, Targher G. Hemostatic abnormalities in endocrine and metabolic disorders. Eur J Endocrinol 2010;162:439-51
54. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev 2008; 29:777-822
55. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008;99:995-1000 (Pubitemid 351810479)
56. Mina A, Favaloro EJ, Koutts J. Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review. Semin Thromb Hemost 2007;33:798-809 (Pubitemid 351158448)
57. Stamler J, Wentworth D, Neaton JD. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am J Med 1986;80: 33-9 (Pubitemid 16131301)
58. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004;24: 584-91 (Pubitemid 38585952)
59. Roberts WC. Getting more people on statins. Am J Cardiol 2002;90:683-5 (Pubitemid 35264559)
60. Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89:1374-80 (Pubitemid 34607777)
61. Gillett Jr RC, Norrell A. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity. Am Fam Physician 2011;83:711-6
62. Garc?a-Compe?n D, J?quez-Quintana JO, Lavalle-Gonz?lez FJ, Reyes-Cabello E, Gonz?lez-Gonz?lez JA, Mu?oz-Espinosa LE, et al. The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. Ann Hepatol 2012;11:240-8
63. Ampuero J, Ranchal I, Nu?ez D, D?az-Herrero Mdel M, Maraver M, del Campo JA, et al. Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PLoS One 2012;7:e49279
64. Jick SS, Stender M, Myers MW. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care 1999;22:2067-71 (Pubitemid 30433990)